Archive · 9 Jan 2026
India Overhauls Antibiotic Regulations to Combat Resistance Crisis
India is facing a big problem with antibiotics not working anymore because people are using them too much or in the wrong way.
This is called antimicrobial resistance (AMR), and it's making people very sick and costing the country a lot of money.
The government is now planning to make big changes to how antibiotics are made, sold, and used.
They want to stop people from buying antibiotics without a prescription, track how they are sold, and make sure they are used correctly.
They also want to develop new antibiotics and make sure old ones are disposed of safely.
Doctors and the government are working together to fix this problem because it's very serious and could make common illnesses much harder to treat.
India's drug regulator proposes overhauling antibiotic development, sale, and monitoring to combat antimicrobial resistance (AMR).
Recommendations include developing new antibiotics, expediting regulatory approvals, and prohibiting over-the-counter (OTC) sales.
AMR causes 267,000 deaths annually in India and could lead to $21 billion in economic losses by mid-century.
Proposed measures include computerized billing, mandatory CCTV monitoring, and an 'Extended Producer Responsibility' (EPR) policy for safe disposal of antibiotics.
The pharmaceutical industry and healthcare experts support the regulations, emphasizing the need for responsible antibiotic use and stricter enforcement.
- Who
- India's top drug regulator, Central Drugs Standard Control Organisation (CDSCO), and a high-level sub-committee of the Drugs Consultative Committee (DCC)
- What
- Overhaul of antibiotic development, sale, and monitoring to combat antimicrobial resistance (AMR)
- When
- Proposed framework based on a report submitted to CDSCO, with recommendations reviewed on 17 November 2023
- Where
- India
- Why
- To address the public health and economic threat of AMR, with 267,000 deaths annually and significant economic losses projected
- Antimicrobial Resistance (AMR) Deaths
- 267,000 annually in India
- Economic Impact
- $21 billion in losses by mid-century
- Antibiotics Market
- $2.9 billion in India
- Schedule H Drugs
- Over 500 prescription-only medications
- Schedule H1 Drugs
- 3rd and 4th generation antibiotics and anti-tuberculosis drugs
- Schedule X Drugs
- Narcotic and psychotropic substances
- National Action Plan on AMR
- Launched in 2017, Phase 2.0 (2025-29) initiated last year
- Pharmaceutical Industry
- $50 billion in India